King’s Higher Bid For Alpharma Still No Ace, Board Says

"Multiple parties" have indicated interest in a business combination with Alpharma, the company's board of directors said in a letter to shareholders Sept. 26, urging them to reject King's $1.6 billion hostile bid for the company